Skip to content
Pirtobrutinib
Jaypirca (pirtobrutinib) is a small molecule pharmaceutical. Pirtobrutinib was first approved as Jaypirca on 2023-01-27. It is used to treat mantle-cell lymphoma in the USA. It is known to target tyrosine-protein kinase BTK.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Jaypirca
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pirtobrutinib
Tradename
Company
Number
Date
Products
JAYPIRCALoxo OncologyN-216059 RX2023-01-27
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
jaypircaNew Drug Application2023-01-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
mantle-cell lymphoma—D020522C83.1
Agency Specific
FDA
EMA
Expiration
Code
PIRTOBRUTINIB, JAYPIRCA, LOXO ONCOL
2030-01-27ODE-424
2028-01-27NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Pirtobrutinib, Jaypirca, Loxo Oncol
103427802036-12-16DS, DP
104649052036-12-16U-3518
106953232036-12-16DS, DPU-3518
109186222036-12-16U-3518
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell chronic lymphocytic leukemiaD015451C91.1244—110
Mantle-cell lymphomaD020522C83.1231—16
Lymphoid leukemiaD007945C91—11——2
B-cell leukemiaD015448——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Waldenstrom macroglobulinemiaD008258C88.022——14
B-cell lymphomaD01639322———3
Non-hodgkin lymphomaD008228C85.912———3
B-cell lymphoma marginal zoneD018442C88.411———2
Large b-cell lymphoma diffuseD016403C83.3—1———1
LeukemiaD007938C95—1———1
Hematologic neoplasmsD019337—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
Multiple myelomaD009101C90.01————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePIRTOBRUTINIB
INNpirtobrutinib
Description
Pirtobrutinib, sold under the brand name Jaypirca, is an anticancer medication that is used to treat mantle cell lymphoma. It inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK). It is taken by mouth.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1
Identifiers
PDB—
CAS-ID2101700-15-4
RxCUI—
ChEMBL IDCHEMBL4650485
ChEBI ID—
PubChem CID129269915
DrugBankDB17472
UNII IDJNA39I7ZVB (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
BTK
BTK
Organism
Homo sapiens
Gene name
BTK
Gene synonyms
AGMX1, ATK, BPK
NCBI Gene ID
695
Protein name
tyrosine-protein kinase BTK
Protein synonyms
agammaglobulinaemia tyrosine kinase, Agammaglobulinemia tyrosine kinase, ATK, B-cell progenitor kinase, BPK, Bruton agammaglobulinemia tyrosine kinase, Bruton tyrosine kinase, Bruton's tyrosine kinase, dominant-negative kinase-deficient Brutons tyrosine kinase
Uniprot ID
Q32ML5
Mouse ortholog
Btk (12229)
tyrosine-protein kinase BTK (Q61365)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 138 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details